Evaluation of the Oncomine Comprehensive Assay Plus NGS Panel and the OncoScan CNV Assay for Homologous Recombination Deficiency Detection
The OCA Plus assay and the OncoScan CNV assay show a high but not complete concordance to reference standard homologous recombination deficiency (HRD) detection. The main reason for QC failure or non-concordance in our study was a low tumor fraction estimated in the assay, despite the selection of material by a pathologist with an inclusion criterion of > 30% tumor. QC steps should include careful tumor content evaluation, and results on samples with < 30% tumor should not be reported.
Authors
- Lone Schejbel (ORCID: https://orcid.org/0000-0003-3677-3227)
- Estrid Høgdall (ORCID: https://orcid.org/0000-0003-4689-5658)
- Lau K. Vestergaard (ORCID: https://orcid.org/0000-0002-4750-4877)
- Ib Jarle Christensen (ORCID: https://orcid.org/0000-0002-3017-7195)
- Tim Svenstrup Poulsen (ORCID: https://orcid.org/0000-0001-9781-0541)
Institutions
- Herlev Hospital (DK)
- Copenhagen University Hospital (DK)
Publication Details
- Journal
- Molecular Diagnosis & Therapy
- Published
- 2024-09-23
- DOI
- https://doi.org/10.1007/s40291-024-00745-7
- Citations
- 3
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Thermo Fisher Scientific
- Københavns Universitet